Potent and sustained satiety actions of a cholecystokinin octapeptide analogue

Timothy H. Moran, Tomi K. Sawyer, Douglas H. Seeb, Peter J. Ameglio, Mark A. Lombard, Paid R. McHugh

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


The relative ability of a norleucine substituted cholecystokinin (CCK) analogue, U-67827E, to interact with CCK receptors and to inhibit food intake was examined across a variety of paradigms. U-67827E and CCK had identical in vitro potencies as demonstrated by their ability to induce pyloric contractions or competitively inhibit [125I]CCK-8 binding to type A and B CCK receptors. However, the in vivo potency of U-67827E was significantly greater than that of CCK-8. In rats, U-67827E inhibited food intake with 10-100 times the potency of CCK. In rhesus monkeys, U-67827E produced significantly greater inhibitions of daily food intake and did so in a dose-dependent manner with no evidence of compensation or tolerance. U-67827E also inhibited gastric emptying for significantly longer durations than CCK. Together these results demonstrate that CCK analogues with increased in vivo bioavailability can affect food intake beyond a single meal.

Original languageEnglish (US)
Pages (from-to)286S-290S
JournalAmerican Journal of Clinical Nutrition
Issue numberSUPPL. 1
StatePublished - Jan 1992


  • Food intake
  • Primates
  • Receptors

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics


Dive into the research topics of 'Potent and sustained satiety actions of a cholecystokinin octapeptide analogue'. Together they form a unique fingerprint.

Cite this